nach oben

Erschienen in:

09.03.2022 | Original Paper

Very early infective endocarditis after transcatheter aortic valve replacement

verfasst von: Vassili Panagides, Mohamed Abdel-Wahab, Norman Mangner, Eric Durand, Nikolaj Ihlemann, Marina Urena, Costanza Pellegrini, Francesco Giannini, Piotr Scislo, Zenon Huczek, Martin Landt, Vincent Auffret, Jan Malte Sinning, Asim N. Cheema, Luis Nombela-Franco, Chekrallah Chamandi, Francisco Campelo-Parada, Erika Munoz-Garcia, Howard C. Herrmann, Luca Testa, Won-Keun Kim, Helene Eltchaninoff, Lars Søndergaard, Dominique Himbert, Oliver Husser, Azeem Latib, Hervé Le Breton, Clement Servoz, Philippe Gervais, David del Val, Axel Linke, Lisa Crusius, Holger Thiele, David Holzhey, Josep Rodés-Cabau

Erschienen in: Clinical Research in Cardiology | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Scarce data exist about early infective endocarditis (IE) after trans-catheter aortic valve replacement (TAVR).

Objective

The objective was to evaluate the characteristics, management, and outcomes of very early (VE) IE (≤ 30 days) after TAVR.

Methods

This multicenter study included a total of 579 patients from the Infectious Endocarditis after TAVR International Registry who had the diagnosis of definite IE following TAVR.

Results

Ninety-one patients (15.7%) had VE-IE. Factors associated with VE-IE (vs. delayed IE (D-IE)) were female gender (p = 0.047), the use of self-expanding valves (p < 0.001), stroke (p = 0.019), and sepsis (p < 0.001) after TAVR. Staphylococcus aureus was the main pathogen among VE-IE patients (35.2% vs. 22.7% in the D-IE group, p = 0.012), and 31.2% of Staphylococcus aureus infections in the VE-IE group were methicillin-resistant (vs. 14.3% in the D-IE group, p = 0.001). The second-most common germ was enterococci (34.1% vs. 24.4% in D-IE cases, p = 0.05). VE-IE was associated with very high in-hospital (44%) and 1-year (54%) mortality rates. Acute renal failure following TAVR (p = 0.001) and the presence of a non-enterococci pathogen (p < 0.001) were associated with an increased risk of death.

Conclusion

A significant proportion of IE episodes following TAVR occurs within a few weeks following the procedure and are associated with dismal outcomes. Some baseline and TAVR procedural factors were associated with VE-IE, and Staphylococcus aureus and enterococci were the main causative pathogens. These results may help to select the more appropriate antibiotic prophylaxis in TAVR procedures and guide the initial antibiotic therapy in those cases with a clinical suspicion of IE.

Graphical abstract

Very early infective endocarditis after trans-catheter aortic valve replacement. VE-IE indicates very early infective endocarditis (≤30 days post TAVR). D-IE indicates delayed infective endocarditis.

Regueiro A, Linke A, Latib A et al (2016) Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA 316:1083–1092. https://doi.org/10.1001/jama.2016.12347CrossRefPubMed

Ando T, Ashraf S, Villablanca PA et al (2019) Meta-analysis comparing the incidence of infective endocarditis following transcatheter aortic valve implantation versus surgical aortic valve replacement. Am J Cardiol 123:827–832. https://doi.org/10.1016/j.amjcard.2018.11.031CrossRefPubMed

Fauchier L, Bisson A, Herbert J et al (2020) Incidence and outcomes of infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement. Clin Microbiol Infect 26:1368–1374. https://doi.org/10.1016/j.cmi.2020.01.036CrossRefPubMed

Summers MR, Leon MB, Smith CR et al (2019) Prosthetic valve endocarditis after TAVR and SAVR: insights from the PARTNER trials. Circulation 140:1984–1994. https://doi.org/10.1161/CIRCULATIONAHA.119.041399CrossRefPubMed

Butt JH, Ihlemann N, De Backer O et al (2019) Long-term risk of infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 73:1646–1655. https://doi.org/10.1016/j.jacc.2018.12.078CrossRefPubMed

Stortecky S, Heg D, Tueller D et al (2020) Infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 75:3020–3030. https://doi.org/10.1016/j.jacc.2020.04.044CrossRefPubMed

Habib G, Lancellotti P, Antunes MJ et al (2015) 2015 ESC Guidelines for the management of infective endocarditis. the task force for the management of infective endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36:3075–3128. https://doi.org/10.1093/eurheartj/ehv319CrossRefPubMed

Kappetein AP, Head SJ, Généreux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60:1438–1454. https://doi.org/10.1016/j.jacc.2012.09.001CrossRefPubMed

Mehta RL, Kellum JA, Shah SV et al (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31. https://doi.org/10.1186/cc5713CrossRefPubMedPubMedCentral

10.

Siciliano RF, Randi BA, Gualandro DM et al (2018) Early-onset prosthetic valve endocarditis definition revisited: prospective study and literature review. Int J Infect Dis 67:3–6. https://doi.org/10.1016/j.ijid.2017.09.004CrossRefPubMed

11.

Benito N, Miró JM, de Lazzari E et al (2009) Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med 150:586–594. https://doi.org/10.7326/0003-4819-150-9-200905050-00004CrossRefPubMedPubMedCentral

12.

Fernández-Hidalgo N, Almirante B, Tornos P et al (2008) Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis 47:1287–1297. https://doi.org/10.1086/592576CrossRefPubMed

13.

Graffunder EM, Venezia RA (2002) Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 49:999–1005. https://doi.org/10.1093/jac/dkf009CrossRefPubMed

14.

Roghmann M-C, Lydecker AD, Hittle L et al (2017) Comparison of the microbiota of older adults living in nursing homes and the community. mSphere 2:e00210-17. https://doi.org/10.1128/mSphere.00210-17CrossRefPubMedPubMedCentral

15.

Bonten MJ, Hayden MK, Nathan C et al (1996) Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. The Lancet 348:1615–1619. https://doi.org/10.1016/S0140-6736(96)02331-8CrossRef

16.

Miller WR, Munita JM, Arias CA (2014) Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther 12:1221–1236. https://doi.org/10.1586/14787210.2014.956092CrossRefPubMedPubMedCentral

17.

Chambers HF, DeLeo FR (2009) Waves of resistance: Staphylococcus aureus in the Antibiotic Era. Nat Rev Microbiol 7:629–641. https://doi.org/10.1038/nrmicro2200CrossRefPubMedPubMedCentral

18.

Engelman R, Shahian D, Shemin R, et al (2007) The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: Antibiotic Choice. Ann Thorac Surg 83:1569–1576. https://doi.org/10.1016/j.athoracsur.2006.09.046

19.

Finkelstein R, Rabino G, Mashiah T et al (2002) Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 123:326–332. https://doi.org/10.1067/mtc.2002.119698CrossRefPubMed

20.

Chenoweth CE, DePestel DD, Prager RL (2005) Are cephalosporins adequate for antimicrobial prophylaxis for cardiac surgery involving implants? Clin Infect Dis 41:122–123. https://doi.org/10.1086/430831 (author reply 123-124)CrossRefPubMed

21.

Baddour LM, Epstein AE, Erickson CC et al (2010) Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 121:458–477. https://doi.org/10.1161/CIRCULATIONAHA.109.192665CrossRefPubMed

22.

Conen A, Stortecky S, Moreillon P et al (2021) A review of recommendations for infective endocarditis prevention in patients undergoing transcatheter aortic valve implantation. EuroIntervention 16:1135–1140. https://doi.org/10.4244/EIJ-D-19-00993CrossRefPubMed

23.

Kachroo S, Dao T, Zabaneh F et al (2006) Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother 40:381–385. https://doi.org/10.1345/aph.1G565CrossRefPubMed

24.

Sambola A, Fernández-Hidalgo N, Almirante B et al (2010) Sex differences in native-valve infective endocarditis in a single tertiary-care hospital. Am J Cardiol 106:92–98. https://doi.org/10.1016/j.amjcard.2010.02.019CrossRefPubMed

25.

Aksoy O, Meyer LT, Cabell CH et al (2007) Gender differences in infective endocarditis: pre- and co-morbid conditions lead to different management and outcomes in female patients. Scand J Infect Dis 39:101–107. https://doi.org/10.1080/00365540600993285CrossRefPubMed

26.

Chandrasekhar J, Dangas G, Yu J et al (2016) Sex-based differences in outcomes with transcatheter aortic valve therapy: TVT registry from 2011 to 2014. J Am Coll Cardiol 68:2733–2744. https://doi.org/10.1016/j.jacc.2016.10.041CrossRefPubMed

27.

Wang HE, Gamboa C, Warnock DG, Muntner P (2011) Chronic kidney disease and risk of death from infection. Am J Nephrol 34:330–336. https://doi.org/10.1159/000330673CrossRefPubMedPubMedCentral

28.

Murdoch DR, Corey GR, Hoen B et al (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169:463–473. https://doi.org/10.1001/archinternmed.2008.603CrossRefPubMedPubMedCentral

29.

Del Val D, Trottier M, Alperi A et al (2020) 18F-Fluorodeoxyglucose uptake pattern in noninfected transcatheter aortic valves. Circ Cardiovasc Imaging 13:e011749. https://doi.org/10.1161/CIRCIMAGING.120.011749CrossRefPubMed

Titel: Very early infective endocarditis after transcatheter aortic valve replacement
verfasst von: Vassili Panagides
Mohamed Abdel-Wahab
Norman Mangner
Eric Durand
Nikolaj Ihlemann
Marina Urena
Costanza Pellegrini
Francesco Giannini
Piotr Scislo
Zenon Huczek
Martin Landt
Vincent Auffret
Jan Malte Sinning
Asim N. Cheema
Luis Nombela-Franco
Chekrallah Chamandi
Francisco Campelo-Parada
Erika Munoz-Garcia
Howard C. Herrmann
Luca Testa
Won-Keun Kim
Helene Eltchaninoff
Lars Søndergaard
Dominique Himbert
Oliver Husser
Azeem Latib
Hervé Le Breton
Clement Servoz
Philippe Gervais
David del Val
Axel Linke
Lisa Crusius
Holger Thiele
David Holzhey
Josep Rodés-Cabau
Publikationsdatum: 09.03.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 10/2022
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-022-01998-0

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Deferral of non-emergency cardiac procedures is associated with increased early emergency cardiovascular hospitalizations

Cardiac affection associated to severe Multisystem Inflammatory Syndrome in Children (MIS-C) in a 6-year-old girl with a single coronary artery

Effect of hyperglycaemia in combination with moxifloxacin on cardiac repolarization in male and female patients with type I diabetes

COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis